Cue Biopharma Net Income

Cue Biopharma posts a net income of $-160M as of June 2026. That compares with $-39M in the prior-year period — down 321.9% year over year. That is below the Healthcare sector average of $17B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Cue Biopharma's net income was $-39M. The latest reading is $-160M — a 321.9% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a net income near $17B is typical. Cue Biopharma's $-160M is lower that level. That is roughly 101.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Cue Biopharma's financial statement story. At $-160M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CUE's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $17B), and (3) consistency with growth and profitability. This page covers the first two; Cue Biopharma's other metric pages and overview cover the third.